BioSpace News Archive

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced corporate and portfolio updates in connection with its participation in the J.P. Morgan Annual Healthcare Conference.

Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced its preliminary, unaudited fourth quarter and full-year 2021 revenue results and expects to exceed the high end of its previously provided fourth quarter 2021 non-GAAP adjusted EBITDA guidance.

Theravance Biopharma, Inc. announced enrollment of the first patient in a Phase 4 study of YUPELRI® inhalation solution, the first and only once-daily, nebulized bronchodilator approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease.

Owens & Minor, Inc. and Apria, Inc. announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion.

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2021.

BIOLASE, Inc., the global leader in dental lasers, announced preliminary 2021 fourth quarter revenue results that are significantly above fourth quarter revenue for both 2020 and pre-COVID 2019.

Moderna Inc. and Carisma Therapeutics Inc. announced that the two companies have entered into a strategic collaboration agreement to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte therapeutics for the treatment of cancer.

Bristol Myers Squibb will highlight progress against the Company’s growth strategy and outlook for 2022 during a presentation scheduled at 7:30 a.m. ET at the 40th Annual J.P. Morgan Healthcare Conference.

Merck, the EORTC and the ETOP announced that the Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression.

Cardinal Health (NYSE: CAH) today provided a fiscal year 2022 financial update for the Medical segment.